In patients with T2DM, finerenone has significant effects on reducing the risk of progression of kidney disease and HHF, whereas GLP1-RA is associated with a lower risk of renal events but has no effect on HHF. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.